232 related articles for article (PubMed ID: 17070061)
1. Vascular disrupting agents.
Lippert JW
Bioorg Med Chem; 2007 Jan; 15(2):605-15. PubMed ID: 17070061
[TBL] [Abstract][Full Text] [Related]
2. The first international conference on vascular targeting: meeting overview.
Thorpe PE; Chaplin DJ; Blakey DC
Cancer Res; 2003 Mar; 63(5):1144-7. PubMed ID: 12615734
[TBL] [Abstract][Full Text] [Related]
3. Current development status of small-molecule vascular disrupting agents.
Chaplin DJ; Horsman MR; Siemann DW
Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
[TBL] [Abstract][Full Text] [Related]
4. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
Cai SX
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
[TBL] [Abstract][Full Text] [Related]
5. Vascular disrupting agents.
Pilat MJ; Lorusso PM
J Cell Biochem; 2006 Nov; 99(4):1021-39. PubMed ID: 16927308
[TBL] [Abstract][Full Text] [Related]
6. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Gridelli C; Rossi A; Maione P; Rossi E; Castaldo V; Sacco PC; Colantuoni G
Oncologist; 2009 Jun; 14(6):612-20. PubMed ID: 19474164
[TBL] [Abstract][Full Text] [Related]
7. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
[TBL] [Abstract][Full Text] [Related]
9. AVE8062: a new combretastatin derivative vascular disrupting agent.
Delmonte A; Sessa C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
[TBL] [Abstract][Full Text] [Related]
10. Vascular disrupting agents in clinical development.
Hinnen P; Eskens FA
Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
[TBL] [Abstract][Full Text] [Related]
11. Vascular damaging agents.
Patterson DM; Rustin GJ
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
[TBL] [Abstract][Full Text] [Related]
12. Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy.
Iversen AB; Busk M; Horsman MR
Acta Oncol; 2013 Oct; 52(7):1320-6. PubMed ID: 23988183
[TBL] [Abstract][Full Text] [Related]
13. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.
McKeage MJ; Baguley BC
Cancer; 2010 Apr; 116(8):1859-71. PubMed ID: 20166210
[TBL] [Abstract][Full Text] [Related]
14. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
Ji YT; Liu YN; Liu ZP
Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and vascular targeting: relevance for hyperthermia.
Horsman MR
Int J Hyperthermia; 2008 Feb; 24(1):57-65. PubMed ID: 18214769
[TBL] [Abstract][Full Text] [Related]
16. Vascular disrupting agents: a new class of drug in cancer therapy.
Gaya AM; Rustin GJ
Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
[TBL] [Abstract][Full Text] [Related]
17. Classification and toxicities of vascular disrupting agents.
Hasani A; Leighl N
Clin Lung Cancer; 2011 Jan; 12(1):18-25. PubMed ID: 21273175
[TBL] [Abstract][Full Text] [Related]
18. Vascular targeting agents as cancer therapeutics.
Thorpe PE
Clin Cancer Res; 2004 Jan; 10(2):415-27. PubMed ID: 14760060
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Horsman MR; Siemann DW
Cancer Res; 2006 Dec; 66(24):11520-39. PubMed ID: 17178843
[TBL] [Abstract][Full Text] [Related]
20. Potential of DMXAA combination therapy for solid tumors.
Baguley BC; Wilson WR
Expert Rev Anticancer Ther; 2002 Oct; 2(5):593-603. PubMed ID: 12382527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
